AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for WD repeat-containing protein 48

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TAF3

UPID:

WDR48_HUMAN

Alternative names:

USP1-associated factor 1; WD repeat endosomal protein; p80

Alternative UPACC:

Q8TAF3; B4DM86; B4DQI2; B4DY84; Q63HJ2; Q658Y1; Q8N3Z1; Q9NSK8; Q9P279

Background:

WD repeat-containing protein 48 (WDR48), also known as USP1-associated factor 1, plays a pivotal role in cellular processes by regulating deubiquitinating complexes. It activates USP1, USP12, and USP46, enhancing the deubiquitination of FANCD2 and positively regulating PHLPP1 stability, acting as a potential tumor suppressor. WDR48 is crucial in DNA repair, working alongside RAD51AP1 to stimulate RAD51-mediated homologous recombination and binds both ssDNA and dsDNA.

Therapeutic significance:

Understanding the role of WD repeat-containing protein 48 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.